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Thecrystal structureofSmCI (Sabellastartemagnifica
carboxypeptidase inhibitor) has been determined in
complex with human carboxypeptidase A4 (hCPA4).
SmCI is composed by three BPTI/Kunitz domains,
each one displaying high structural homology and
functionality with serine protease inhibitors. More-
over, SmCI possesses a distinctive capability to
inhibit metallo-carboxypeptidases, constituting a
bifunctional metallocarboxy- and serine protease
inhibitor. The structure of the 1:1 complex of SmCI
with hCPA4 reveals a noncanonical mechanism of
carboxypeptidase inhibition, which surprisingly
occursmainly via theN-terminal segment,which pen-
etrates into the active site groove of the enzyme.
Mutagenesis and biochemical analysis confirm the
major role of the N-terminal segment in the inhibition
of carboxypeptidases. SmCI represents a tri-Kunitz
serine protease inhibitor adapted to inhibit metallo-
carboxypeptidases and discloses an unusualmecha-
nism of inhibition by the N-terminal segment,
emulating the ‘‘classical’’ C-terminal substrate-like
inhibition.
INTRODUCTION
Metallo-carboxypeptidases (MCPs) are enzymes involved in a
variety of physiologic processes in organisms, ranging from
food digestion (pancreatic enzymes) to regulatory functions
such as hormone and neuropeptide processing, inflammation,
and coagulation/fibrinolysis, among others (Arolas et al., 2007).
In previous decades, due to the important biomedical roles
assigned for these enzymes (with potential as a therapeutic
target in cancer, and in allergic and cardiovascular diseases),
the quest for natural protein inhibitors of MCPs has increased
(Ferna´ndez et al., 2010; Rodrı´guez de la Vega Otazo et al.,
2013). Unlike endoproteases, for which a large number of exam-1118 Structure 21, 1118–1126, July 2, 2013 ª2013 Elsevier Ltd All rigples of natural protein inhibitors have been reported, only a few
of them are known for MCPs. Protein inhibitors of MCPs have
been identified and characterized from the following sources:
in Solanacea, i.e., tomato and potato (PCI) (Arolas et al., 2007;
Rees and Lipscomb, 1982); in the intestinal parasite Ascaris
suum (ACI) (Sanglas et al., 2009); in the medicinal leech Hirudo
medicinalis (LCI) (Reverter et al., 2000); in the ticksRhipicephalus
bursa (TCI) (Arolas et al., 2005) and Haemaphysalis longicornis
(H1TCI) (Gong et al., 2007); in the mollusk Nerita versicolor
(NvCI) (Covaleda et al., 2012); in rat and human tissues (latexin
or ECI) (Normant et al., 1995; Pallare`s et al., 2005); and recently
in the marine annelid Sabellastarte magnifica (SmCI) (Alonso del
Rivero et al., 2012).
Detailed structural and functional characterization has dis-
closed the inhibitory mechanisms of PCI, LCI, ACI, TCI, and
NvCI on MCPs, which basically rely upon the interaction of their
two-to-four residues of the carboxyl terminal tail with the active
site cleft of the enzyme in a manner that mimics substrate bind-
ing (Rees and Lipscomb, 1982; Sanglas et al., 2009; Reverter
et al., 2000; Arolas et al., 2005; Covaleda et al., 2012). The
homology observed between the C-terminal tails of MCP inhibi-
tors from all these distant organisms constitutes a clear example
of convergent evolution dictated by the target protease (Cova-
leda et al., 2012). The only known protein inhibitor of MCPs
that differs in the inhibition mechanism is latexin, in which the
interaction with carboxypeptidases is carried out in a way that
mimics autologous inhibition by the activation segment of pro-
carboxypeptidases (Vendrell et al., 2000), binding the top of
the enzyme through the interface of the two domains of latexin
(Normant et al., 1995).
SmCI is a 19.7 kDa glycoprotein recently isolated from the
tentacle crown of the marine annelid Sabellastarte magnifica
that is formed by three consecutive BPTI/Kunitz-like domains
(Alonso del Rivero et al., 2012). SmCI displays strong inhibition
against serine proteases and metallo-carboxypeptidases and
constitutes an example of a multidomain Kunitz inhibitor with a
dual-inhibitory capability against these two distinct mechanistic
classes of proteases (Alonso del Rivero et al., 2012). SmCI can
inhibit the S1 family of serine proteases such as trypsin, elastase,
and chymotrypsin, with Ki values around the nanomolar range for
the first two, and a weaker value (Ki 107 M) for the latter. Also,hts reserved
Table 1. Data Collection and Refinement Statistics
Parameter SmCI-hCPA4
Data Collection
Space group P6522
Cell Dimensions
a, b, c (A˚) 138.42, 138.42, 161.99
a, b, g () 90.0, 90.0, 120.0
Resolution (A˚) 48–2.1 (2.2–2.1)a
Rsym or Rmerge 0.10 (0.65)
I/sI 7.5 (2.2)
Completeness (%) 99.5 (98.4)
Redundancy 3.3 (3.4)
Refinement
Resolution (A˚) 2.2
No. reflections 46,623
Rwork/Rfree 22.31/25.38
No. of Atoms
Protein 3,706
Ligand/ion 1
Water 123
B Factors (mean)
Protein (A˚2) 38.34
Ligand/zinc (A˚2) 27.75
Water (A˚2) 31.38
Rmsds
Bond lengths (A˚) 0.008
Bond angles () 1.133
aValues in parentheses are for highest-resolution shell.
Structure
Crystal Structure of SmCI-hCPA4SmCI can inhibit type A carboxypeptidases with a slow tight
binding kinetics mechanism, displaying inhibitory constants in
the nanomolar values, such as for bovine CPA1 (Ki value of
14.8 nM). However, unlike other MCPs inhibitors, SmCI cannot
inhibit type-B carboxypeptidases. Recombinant forms of this
inhibitor, including the nonglycosylated mutant N23A (termed
SmCI N23A) can be efficiently produced in the Pichia pastoris
system and display the same dual-inhibitory capabilities as the
natural form (Alonso del Rivero et al., 2012). Moreover, functional
analysis carried out with two truncated constructs of SmCI
(D1-D2 and D2-D3 BPTI/Kunitz bidomains) indicated that only
SmCI bidomain D1-D2 is able to inhibit carboxypeptidase, but
in a lesser degree compared to the SmCI tridomain inhibitor.
These results together with the lack of carboxypeptidase inhibi-
tion displayed by the third SmCI domain (D3 BPTI/Kunitz
domain) suggested that the inhibitory mechanism does not rely
on the carboxyl terminal end of the molecule (Alonso del Rivero
et al., 2012), as occurs for the other known protein inhibitors of
MCPs (Rees and Lipscomb, 1982; Sanglas et al., 2009; Reverter
et al., 2000; Arolas et al., 2005; Covaleda et al., 2012).
Kunitz-type domains have been described either as a single-
domain protein, such as the model member of the family, BPTI
(bovine pancreatic trypsin inhibitor), or as multidomain proteins
containing multiple tandem repeats of the BPTI/Kunitz domain.
BmTI-A and boophilin from the cattle tick Boophilus microplus,Structure 21, 1and bikunin from human are examples of multidomain proteins
composed of two-tandem BPTI/Kunitz domains (Xu et al.,
1998; Zhuo et al., 2004; Sasaki et al., 2004; Soares et al.,
2012). TFPI1 and TFPI2 (tissue factor pathway inhibitors 1
and 2) from human and BmTI-6 from the cattle tick Boophilus
microplus are examples of three tandem BPTI/Kunitz multido-
main proteins (Wun et al., 1988; Sprecher et al., 1994; Du
et al., 2003; Sasaki and Tanaka, 2008). In all of these examples,
the multi-Kunitz inhibitors act on proteolytic enzymes belonging
to the same mechanistic class, typically affecting the activity of
serine proteases involved in the blood coagulation cascade.
However, atypically for SmCI, which is built up by three tandem
BPTI/Kunitz domains, the inhibitory activity is bifunctional
against two different mechanistic classes of proteases: MCPs
and serine proteases.
In this work, we report the crystal structure of SmCI, a three
tandem BPTI/Kunitz domain inhibitor, in complex with hCPA4
at 2.2 A˚ resolution. The SmCI in complex with hCPA4 discloses
a noncanonical mechanism for MCP inhibition conducted by the
N-terminal segment of the inhibitor. The details of the binding of
hCPA4 by SmCI reveal the structural and molecular reasons by
which a canonical multi-Kunitz serine protease inhibitor is able
to inhibit MCPs. This inhibition may constitute a paradigmatic
example of convergent evolution dictated by the carboxy-
peptidase target enzyme but, in this instance, carried out by
the N-terminal segment and not by the C-terminal tail, as occurs
in all known reported ‘‘canonical’’ MCP inhibitors.
RESULTS
Protein Recombinant Production and Complex
Formation
The recombinant form of SmCI was produced in Pichia pastoris
as described recently (Alonso del Rivero et al., 2012). To
enhance crystallization of SmCI, a point mutant in which the
glycosylation site has been removed (N23A) was produced in
P. pastoris and purified as the recombinant wild-type protein
(rSmCI) (see Experimental Procedures) (Alonso del Rivero
et al., 2012). SmCI (N23A) expression yielded 5.0mg of the inhib-
itor/L of culture broth and displayed similar inhibitory properties
against trypsin and CPA as the natural and recombinant wild-
type forms (Alonso del Rivero et al., 2012). The enzyme counter-
part, human hCPA4, was also produced in P. pastoris with an
overall yield of 17.6 mg hCPA4/L culture medium. The complex
of both counterparts was formed with a 1:1 molar ratio
(hCPA4:SmCI) and purified by gel filtration as a single elution
peak (see Experimental Procedures for details).
Crystal Structure of the SmCI in Complex with hCPA4
Crystals of the complex between SmCI (N23A) and hCPA4 dif-
fracted beyond at 2.2 A˚ (Table 1). The polypeptide chain of
both counterparts, hCPA4 and SmCI (N23A), could be clearly
and completely traced in the electron density maps (Asn5 to
Leu308 for hCPA4, and Ile1 to Cys165 for SmCI) (Figure 1).
The crystal structure of SmCI (N23A)-hCPA4 displays one com-
plex in the asymmetric unit. Based on results obtained with gel
filtration chromatography, the biologic unit is considered to be
a monomer, formed only by one binary complex between
hCPA4 and SmCI.118–1126, July 2, 2013 ª2013 Elsevier Ltd All rights reserved 1119
Figure 1. Three-Dimensional Structure of
the Complex between SmCI N23A and
Human hCPA4
(A) Ribbon representation of the complex SmCI-
hCPA4. SmCI domains are labeled and blue;
hCPA4 is red; and the catalytic zinc atom in hCPA4
is green. The three-disulfide bridges formed in
each SmCI domain are shown in stick represen-
tation and are yellow. The N-termini is labeled Nt.
(B) Surface representation of hCPA4 (red) in com-
plex with SmCI shown in ribbon representation
(blue). AS indicates the position of the active site
groove of hCPA4.
(C) Stereo view in ribbon representation of the
backbone trace of the complex SmCI-hCPA4.
SmCI domains are labeled and blue; hCPA4 is red;
and the catalytic zinc atom in hCPA4 is a green
sphere. The three disulfide bridges formed in SmCI
are shown in stick representation (green). The N
and C termini are labeled N or C, respectively. All
figures were prepared with PyMOL (The PyMOL
Molecular Graphics System, Version 1.5.0.4
Schro¨dinger).
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Crystal Structure of SmCI-hCPA4As previously predicted from sequence homology analysis,
the structure of SmCI confirms the presence of three consecu-
tive BPTI/Kunitz domains. Each of the three domains of SmCI
displays the characteristic fold of the BPTI/Kunitz family of serine
protease inhibitors, which is composed of a central antiparallel
beta sheet with one short alpha helix at the C-terminal end.
Also, each domain is characterized by the presence of three
disulfide bridges, displaying the distinct disulfide bridge pattern
found in BPTI/Kunitz domains (CysI-CysVI, CysII-CysIV, CysIII-
CysV (Figures 1 and 2). The top homologous structures found
by structural alignment software (PDBefold) belong to the
family of BPTI/Kunitz inhibitors, namely SHPI-1 (Stichodactyla
helianthus protein inhibitor, Protein Data Bank [PDB] code
3T62), APPI (amyloid precursor protein inhibitor, PDB code
1CA0), and Aprotinin (PDB code 3GYM). All these structures
display root-mean-square deviations (rmsds) between 0.48
and 0.71 A˚ with each of the three domains of SmCI. Interestingly,
the SmCI domains in the current structure display rmsds
between 0.67 and 0.72 A˚ with each other, with sequence identity
ranging between 39% and 48%. In the current crystal structure
of the complex between SmCI (N23A) and hCPA4, the reactive
subsite residues for serine protease inhibition, P3 to P30 (based
on Schechter and Berger nomenclature, in which substrate/
inhibitor residues are denoted by Pn,., P1-P10,., Pm0, from
N to C terminal, where P1-P1
0 is the scissile peptide bond;
Bode and Huber, 2000) are located in the opposite face
of the carboxypeptidase binding interface (Figure 1), envision-1120 Structure 21, 1118–1126, July 2, 2013 ª2013 Elsevier Ltd All rights reserveding a possible scenario of simultaneous
serine protease and carboxypeptidase
inhibition.
SmCI is composed of three BPTI/Kunitz
domains (D1, D2, and D3) linked in tan-
dem by two connecting loops and con-
taining only a short N-terminal extension.
In the complex with hCPA4, the D1 and
D2 domains are located next to eachother, establishing a total interface of 856 A˚2. A total number of
13 and 15 residues from D1 and D2 domains, respectively,
form this interface, which is composed of a mixture of polar
and hydrophobic interactions. In particular, a hydrophobic core
can be observed among Ile51, Cys56, Phe96, and Val105, all res-
idues emanating from the helices a1 and a2 (Figure 2B). How-
ever, the D3 domain is not in contact with the other two domains
due to the presence of a longer connecting loop between the D2
and D3 domains (Figures 1 and 2). The D3 domain may adopt
different orientations in the absence of the hCPA4, which
restricts the SmCI conformation to the one present in the com-
plex structure.
The N-terminal extension of SmCI is formed by three residues
(ISV) and as described later in the text, this extension is essential
for the MCPs inhibition (Figure 2C). The connecting loop
between the D1 and D2 domains is only formed by one residue
(G), which facilitates the formation of the aforementioned inter-
face between D1 and D2 domains. However, the connecting
loop between D2 and D3 domains comprises eight residues
(DRYQKPGF) and is important for the inhibition of carboxypepti-
dases by the establishment of an extended interface with
hCPA4. SmCI does not present any C-terminal extension and
the tri-Kunitz inhibitor ends up with a characteristic disulfide
bridge formed by the C-terminal cysteine residue of the protein.
hCPA4 displays the canonical MCPs structure, which is
composed of eight a helices and a mixed eight-stranded b sheet
forming a globular a/b motif (Figure 1) and is related to previous
Figure 2. Structure of the Tri-BPTI/Kunitz
SmCI Inhibitor
(A) Ribbon representation of the three BPTI-Kunitz
domains of SmCI in the crystal structure of the
complex SmCI-hCPA4. SmCI domains are labeled
and blue; secondary structure elements are
labeled and shown in cartoon representation. The
three disulfide bridges from each SmCI domain
are shown in stick representation and are yellow.
The N terminus is labeled Nt.
(B) Surface representation of the figure depicted in
(A). Amino acid residues corresponding to the
interface between the D1 and D2 domains are
labeled and shown in stick representation.
(C) Amino acid sequence of the structural align-
ment of the three domains of SmCI. Gaps are
denoted by (-). Numbering above the sequence
alignment corresponds to the amino acid position
in SmCI. Secondary structural elements are indi-
cated above the alignment. b strands and a helices
are numbered and coil depicted as a line. Red dots
below the sequence indicate interaction with the
carboxypeptidase domain. The disulphide bridge
pairing is indicated below each domain.
Structure
Crystal Structure of SmCI-hCPA4hCPA4 structures (Normant et al., 1995; Covaleda et al., 2012).
The coordination of the zinc atom is essentially conserved
when compared with other MCPs structures. Normally, in the
absence of the inhibitor, the zinc atom is coordinated to the ‘‘cat-
alytic’’ water molecule and to the MCP residues His69, His196,
and in a bidentate form to Glu72 (Normant et al., 1995; Covaleda
et al., 2012). However, in the present structure of hCPA4 in com-
plex with SmCI (N23A), the catalytic water is still coordinated to
the zinc atom and to the N-terminal amino group of the SmCI,
which is buried in the active site groove of the enzyme (Fig-
ure 1B). The most dramatic change observed in the active site
is the movement of the side chain of Tyr248, almost 180 from
the ‘‘up’’ to the ‘‘down’’ position in the complex. The ‘‘down’’
or ‘‘closed’’ orientation of Tyr248 is characteristic ofMCPs struc-
tures with active sites occupied by substrates or inhibitors
(Sanglas et al., 2009; Arolas et al., 2005; Covaleda et al., 2012;
Normant et al., 1995).
All three BPTI/Kunitz domains of SmCI are in contact with
hCPA4, with the D1 and D2 domains covering the active site
region of the enzyme and precluding substrate entrance (Figures
1 and 2C). Remarkably, a mechanism of MCPs inhibition is dis-
closed in the present SmCI (N23A)-hCPA4 complex in which
instead of being the C-terminal tail, it is actually the N-terminal
extension of the inhibitor that penetrates the MCP active site
groove and interacts with key residues of hCPA4. Thus, despite
being an enzyme with carboxypeptidase activity (cleaving off
C-terminal residues of proteins and peptides), a substrate-like
inhibition can take place by the amino N-terminal segment,
emulating most of the interactions performed by the carboxylic
C-terminal tail of substrates and inhibitors of MCPs.
N-Terminal Segment Interaction of SmCI with hCPA4
Despite its short length (ISV), the N-terminal extension of SmCI
interacts extensively with hCPA4 active site groove (Figure 3).
In all C-terminal inhibitors of MCPs (PCI, LCI, ACI, TCI, andStructure 21, 1NvCI), inhibition takes place by a substrate-like competitive
interaction of the C-terminal tail of the inhibitor with occlusion
of the active site subsites S10, S1, S2, and S3 (Rees and Lips-
comb, 1982; Sanglas et al., 2009; Reverter et al., 2000; Arolas
et al., 2005; Covaleda et al., 2012). However, the N-terminal
segment of SmCI seems to produce a similar substrate-like inhi-
bition, but in this case by occluding only the active site subsites
S1 and S2. Therefore, the amino N-terminal segment of SmCI
constitutes the ‘‘primary’’ contact region of the inhibitor,
emulating a noncleavable carboxylic substrate.
The residues Ile1, Ser2, and Val3 forming the N-terminal
segment of SmCI correspond to the P1, P2, and P3 subsite
positions. According to the electron density maps, in the
SmCI (N23A)-hCPA4 complex structure, the S10 subsite does
not appear to be occupied as in other inhibitors of MCPs in
which the last (C-terminal) residue of the inhibitor is cleaved
off and trapped in the S10 subsite of the enzyme (composed
of Asn144 and Arg145 in MCPs). In the case of the amino
N-terminal extension of SmCI, such S10 interaction cannot
take place because carboxypeptidases have never displayed
any aminopeptidase activity. The electron density map shows
an ordered water molecule in the S10 subsite of the hCPA4
active site.
Despite the lack of sequential and structural homology
between the MCP inhibitors described so far, the three N-termi-
nal segment residues of SmCI display similar positions for
backbone and side chains when compared to the C-terminal
inhibitors of MCPs (Figures 3C and 3D). The only amino acid
conserved in SmCI might be found in the P1 position, Ile1, nor-
mally occupied by an aliphatic residue in all other C-terminal
MCPs inhibitors (Ala, Val, or Ile) (Figure 3D). The aliphatic side
chain of Ile1 is buried in the S1 subsite pocket formed by the
side chains of Tyr198, Val247, and Tyr248 in hCPA4. However,
the P2 position that is normally occupied by an aromatic or a
heavily aliphatic residue in all C-terminal MCPs inhibitors (Tyr,118–1126, July 2, 2013 ª2013 Elsevier Ltd All rights reserved 1121
Figure 3. Close-Up View of the SmCI N-Terminal Segment in
Complex with hCPA4
(A) Close-up stereo view in stick representation of the N-terminal segment of
SmCI with the active site of hCPA4. Amino acid residues corresponding to the
N terminus of SmCI and the active site of hCPA4 are labeled and shown in blue
and gray, respectively. The active site zinc is shown as a green sphere,; and
the active site water molecule is shown as a red sphere.
(B) Close-up stereo view of the 2Fc-Fo electron density map of the N-terminal
segment of SmCI with the active site of hCPA4 shown in stick representation.
Amino acid residues corresponding to the N terminus of SmCI and the active
site of hCPA4 are labeled and shown in gray and yellow, respectively. The
active site zinc is shown as a green sphere, and the active site water molecules
are shown as gray spheres.
(C) Stereo representation of the structural alignment of the N-terminal segment
of SmCI (blue) with the C-terminal tail of TCI (yellow). Amino acid residues are
shown in stick representation. Amino acid residues corresponding to the
Structure
Crystal Structure of SmCI-hCPA4
1122 Structure 21, 1118–1126, July 2, 2013 ª2013 Elsevier Ltd All rigTrp, except a Leu residue in ACI) is formed by a serine residue in
SmCI. In C-terminal MCPs inhibitors, the aromatic side chain of
P2 establishes stacking interactions with the aromatic ring of the
‘‘mobile’’ Tyr248. In the SmCI-hCPA4 complex, despite a similar
‘‘down’’ orientation of the side chain of Tyr248, the side chain of
P2 (Ser2) does not interact with any hCPA4 residue (Figure 3).
Strikingly, despite the opposite backbone direction in the
N-terminal extension when compared to the C-terminal MCPs
inhibitors, similar backbone hydrogen bonds are established
with hCPA4. The amino terminal group of Ile1 is in contact with
the ‘‘catalytic’’ water (at 2.44 A˚), which is also in contact with
the zinc atom (at 2.17 A˚), with the backbone carbonyl oxygen
of Ser197 (at 2.77 A˚) and with the side chain of Glu270 (at
2.93 A˚). Although the amino group of SmCI has a similar position
as the C-terminal carboxylate group in C-terminal MCPs inhibi-
tors, it does not interact directly with the zinc atom, but does
so through a water molecule. The lack of such strong interaction
with the zinc atom could be the reason for the lower inhibitory
capability (higher Ki) in SmCI regarding the C-terminal MCPs
inhibitors (Alonso del Rivero et al., 2012).
Interestingly, the backbone carbonyl oxygen of Ile1 interacts
with the guanidinum group of Arg71 of hCPA4 (at 3.05 A˚) (Fig-
ure 3A). This interaction is conserved in the C-terminal MCPs
inhibitors, in that case involving the backbone carbonyl oxygen
of the P2 residue. Additionally, the amino group of Ser2 forms
a hydrogen bond with the hydroxyl side chain oxygen of
Tyr248 (at 2.83 A˚), which is in the ‘‘down’’ conformation (when
bound to substrates). This interaction is also conserved in the
C-terminal MCPs inhibitors but involves the amino group of the
P1 residue in that case. So, despite the different backbone direc-
tions for the N- and C-terminal tails inside the active site of
hCPA4, the relative position of the P1 and P2 residues and all
the interactions, except the ones directly established by the
C-terminal carboxylate group, are conserved between the C-ter-
minal ‘‘classical’’ inhibitors and the noncanonical SmCI tri-Kunitz
inhibitor (Figure 3D).
Mutational Analysis of the N-Terminal Segment of SmCI
Consequently, the amino N-terminal segment of SmCI partially
behaves as a substrate-like inhibitor despite being neither a
carboxylate-ended molecule nor cleaved off as the usual ones
(Reverter et al., 2000). To demonstrate experimentally the role
of the amino N-terminal segment of SmCI in MCP inhibition,
we have constructed a N-terminal truncated mutant of SmCI
(N23A) (SmCI-DIS-N23A), in which the first two residues of
SmCI (Ile1 and Ser2) are removed. We conducted kinetic inhibi-
tory measurements against serine proteases (trypsin and elas-
tase) and carboxypeptidases (bCPA1, pCPA, hCPA1, and
hCPA4) and compared the inhibitory constants (Ki) of both the
SmCI (N23A) and the N-terminal truncated mutant (SmCI-DIS/
N23A). The results of such kinetics analyses are summarized in
Table 2. As expected for serine proteases, with either trypsin
or elastase, the inhibitory constants are not affected, displayingactive site of hCPA4 are labeled and shown in gray. The active site zinc is
shown as a green sphere.
(D) Sequence alignment of the N-terminal segment of SmCI with the C-terminal
tails of other exogenous proteinaceous carboxypeptidase inhibitors, depicting
the P1, P2, P3, and P10 subsites.
hts reserved
Table 2. Comparison of Ki Values of the Nonglycosylated
Tridomain Forms of SmCI—SmCI N23A–and Its N-Terminal
Mutant—SmCI N23A-DIS—against Enzymes
Enzyme SmCI N23A (mol/l) SmCI N23A-DIS (mol/l)
hCPA4 3.10 ± 0.60 3 108 NI
bCPA1 2.42 ± 0.13 3 108 NI
hCPA1 6.19 ± 0.58 3 109 NI
pCPA 2.42 ± 0.13 3 108 NI
Pancreatic trypsin 1.23 ± 0.61 3 1010 1.34 ± 0.67 3 1010
Pancreatic elastase 1.08 ± 0.18 3 109 4.46 ± 0.49 3 109
h, human; b, bovine; NI, no inhibition; p, pancreatic.
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Crystal Structure of SmCI-hCPA4similar Ki values for the SmCI (N23A) and N-terminal truncated
mutant of SmCI. These results indicate that the N-terminal region
of SmCI does not interfere in the activity of serine proteases.
However, in the case of the two carboxypeptidases tested,
bCPA1 and hCPA4, the results are opposed, displaying in both
cases a total absence of CP inhibition by SmCI for the N-terminal
truncated SmCI. These results confirm unequivocally the main
role of the ‘‘primary’’ interaction performed by the N-terminal
extension, which penetrates the active site groove of the enzyme
emulating a C-terminal substrate, despite being the backbone
atoms of the N-terminal segment in an opposite direction.
‘‘Secondary’’ Binding Interface of SmCI with hCPA4
The ‘‘secondary’’ interaction region of SmCI is quite extended
and composed of contacts from the three BPTI/Kunitz domains
with regions distant from the active site of hCPA4 (Figures 1
and 4). ‘‘Secondary’’ binding regions contribute substantially to
the decrease of the inhibitory constant by the stabilization of
the complex and allowing an optimal orientation for the entrance
of the C-terminal tail (N-terminal in SmCI) into the active site of
the enzyme (Arolas et al., 2004, 2005). Among the large number
of contacts among the three BPTI/Kunitz domains with hCPA4,
the major secondary binding interface can be clearly identified
in the loop connecting the D2 and D3 domains. Besides several
van der Waals interactions, the D2-D3 connecting loop is
composed of four specific hydrogen bond interactions between
the backbone atoms of SmCI and hCPA4 (Figure 4). The back-
bone hydrogen bonds are formed between the SmCI carbonyl
oxygens of Tyr109 and Lys111 with the backbone nitrogen of
Leu125 (at 3.34 A˚) and Arg124 (at 2.74 A˚), respectively, and
between the SmCI backbone nitrogens of Gly113 and Phe114
with the backbone carbonyl oxygens of Thr119 (at 2.80 A˚) and
Gln120 (at 3.51 A˚), respectively (Figure 4B). In addition to these
polar interactions, the D2-D3 connecting loop also displays
hydrophobic interactions, which are basically formed between
SmCI Tyr116 and Tyr135 with the aliphatic chain of Arg124 (at
3.43 A˚) and Val280 (at 3.72 A˚), respectively.
DISCUSSION
The tri-Kunitz SmCI represents an example of a protein inhibitor
with a dual/mixed activity on MCPs and serine proteases. The
structure of each of the three domains of SmCI displays the char-
acteristic fold of the BPTI/Kunitz family, which is a well-known
family of serine protease inhibitors (Huber et al., 1974). Interest-Structure 21, 1ingly, each canonical BPTI/Kunitz domain of SmCI contains a
particular residue at the P1 position, which would probably result
in a broad inhibition range against different serine proteases
(Alonso del Rivero et al., 2012). This is a clear benefit of themulti-
domain Kunitz inhibitors in which the presence of different BPTI/
Kunitz domains covers the inhibition capability toward different
serine protease specificities. Examples of multidomain Kunitz
protein inhibitors in mammals include TFPIs 1 and 2, present in
blood and containing three tandem BPTI/Kunitz domains
capable of inhibiting different types of serine proteases/blood
clotting factors (Wun et al., 1988; Sprecher et al., 1994; Du
et al., 2003); and bikunin, a bidomain Kunitz inhibitor found in
placenta and urine, able to inhibit plasmin, trypsin, and elastase
(Xu et al., 1998; Zhuo et al., 2004). Also, from the invertebrate
cattle tickBoophilusmicroplus, several multidomain BPTI/Kunitz
inhibitors have been isolated, including BMTI-A, boophilin, and
BMTI-6. All are involved in the inhibition of blood clotting serine
proteases, such as thrombin, required for this parasite’s suc-
cessful feeding and digestion (Sasaki et al., 2004; Soares
et al., 2012; Sasaki and Tanaka, 2008).
In addition to the serine protease-like canonical inhibition, a
characteristic found in somemembers of themultidomain Kunitz
family is their ability to inhibit some serine proteases in nonca-
nonical manners, as described for the bidomain Kunitz inhibitor
boophilin and for the bidomain distorted Kunitz inhibitor ornitho-
dorin (Macedo-Ribeiro et al., 2008; van de Locht et al., 1996).
The structures of these two inhibitors in complex with their target
protease, thrombin, has revealed an alternative inhibitory mech-
anism in which the canonical P1 residue is still exposed to the
solvent and able to inhibit a second trypsin-like proteinase in a
canonical manner without steric hindrances, allowing the forma-
tion of ternary complexes (Macedo-Ribeiro et al., 2008). In SmCI
presented in this study, the modular composition of the three
tandem BPTI/Kunitz domains has allowed the optimization of
the amino acid links among the three domains to act on MCPs.
This inhibition is made possible by the acquisition of an inter-
acting N-terminal extension at the D1 domain and by the pres-
ence of a long connecting loop between the D2 and D3 domains.
It is remarkable that the required changes on the SmCI structure
to inhibit MCPs occur on regions not involved in the inhibition of
serine proteases, basically in the loop connections outside the
core of the three BPTI/Kunitz domains. Therefore it is possible
to envision a scenario of dual inhibition of serine and MCPs by
the tri-Kunitz SmCI, because the active site inhibitory residues
against these two types of proteases are located in opposite
faces of the inhibitor, as shown in the crystal structure of the
complex between SmCI (N23A)-hCPA4.
The SmCI (N23A)-hCPA4 complex structure reveals a nonca-
nonical inhibition mechanism against MCPs, mainly conducted
by the N-terminal segment of SmCI. Interestingly, despite the
opposite orientation of the backbone chain between the N-
and C-terminal tails, similar hydrogen bonds can take place
with the P1 and P2 subsites. Removal of these two residues
(Ile1 and Ser2) completely abolishes the inhibition of MCPs.
Kinetic measurements have also revealed a slow tight binding
inhibitory mechanism against MCPs (Alonso del Rivero et al.,
2012). A plausible explanation for such kinetic behavior could
be the difficult requirements for the N-terminal segment inhibitor
to be accommodated in the active site of the enzyme.118–1126, July 2, 2013 ª2013 Elsevier Ltd All rights reserved 1123
Figure 4. Close-Up View of the SmCI
‘‘Secondary’’ Binding Region in Complex
with hCPA4
(A) Ribbon representation of the ‘‘secondary
binding’’ region, loop connection between D2 and
D3 domains, of SmCI in complex with hCPA4.
Amino acid residues corresponding to SmCI and
hCPA4 are shown in blue and gray, respectively.
(B) Close-up stereo view in stick representation of
the loop connection between the D2 and D3 SmCI
domains. Amino acid residues corresponding to
SmCI and hCPA4 are labeled and shown in blue
and gray, respectively.
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Crystal Structure of SmCI-hCPA4Interestingly, carboxypeptidase inhibition by the N-terminal
segment of SmCI is similar to the inhibition of matrix metallo-
proteinases (MMP) by the TIMP inhibitors (tissue inhibitor of
matrix metallo-proteinases), although in that case the specific
contacts of the N-terminal segment with the active sites of
MMPs are different in the SmCI-hCPA4 interaction (Gomis-
Ru¨th et al., 1997).
In addition to the major contribution of the N-terminal
segment, a ‘‘secondary’’ interface in SmCI is necessary for the
MCPs inhibition. This has been recently supported experimen-
tally by the kinetic analysis of truncated SmCI bidomain con-
structs (Alonso del Rivero et al., 2012). The third domain D3 as
well as the bidomain D2-D3 alone did not produce any carboxy-
peptidase inhibition, probably due to the lack of the N-terminal
segment. However, the bidomain D1-D2 of SmCI displays an in-
crease of two orders of magnitude in the inhibitory constant
(Ki 106, compared to the tridomain Ki 108) (Alonso del Riv-
ero et al., 2012). The presence of the secondary interaction site in
the complex (mainly provided by the D2-D3 connecting loop)
probably produces a loss of entropy in the binding that favors
the interaction of the N-terminal segment on the active site cleft
of the enzyme and contributes to the stabilization of the complex.
The overall SmCI interface with hCPA4 is quite extensive and
involves contacts from the three BPTI/Kunitz domains, covering1124 Structure 21, 1118–1126, July 2, 2013 ª2013 Elsevier Ltd All rights reserveda total surface area of 2,086 A˚2.
The SmCI interface is only comparable
in size to the interface created by
the two-domain tick carboxypeptidase
inhibitor (TCI) when bound to CPA1,
with a total surface area of 2,108 A˚2
(Sanglas et al., 2009). Interestingly,
despite the completely different three-
dimensional structures between SmCI
and TCI, they interact with the same
regions on the CP surface. In all known
structures of exogenous C-terminal pro-
teinaceous inhibitors in complex with
MCPs (LCI, ACI, PCI, NvCI), a ‘‘second-
ary’’ interaction site is always present
but displays different interfaces with the
MCP. In the case of the endogenous
MCPs inhibitors, latexin from human
and rat tissues and the prodomains
from mammalian carboxypeptidase A/Bprecursors, the structures and the inhibitory interfaces are
unrelated to SmCI.
Thus, the structure of the complex between deglycosylated
SmCI (N23A) and hCPA4 reported here revealed a noncanonical
inhibition of carboxypeptidases by a multi-Kunitz serine prote-
ase inhibitor. It seems, therefore, that the molecular evolution
has provided a variety of structures and mechanisms for the
inhibition of MCPs, which previously were observed for other
catalytic types, like serino and metallo-endoproteases.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents
All chemicals were reagent grade. Chromatographic columns were obtained
from GE Healthcare (USA); bovine pancreatic carboxypeptidase A1, bovine
pancreatic trypsin, porcine pancreatic elastase, and p-nitrophenyl-p-guanidi-
nobenzoate (NPGB) were purchased from Sigma (USA). Benzoyl-arginyl-
pNA (BAPA), N-(4-methoxyphenylazoformyl)-L-phenylalanine (AAFP), and
MeOSuc-(L-Ala)2-L-Pro-L-Val-p-nitroanilide were supplied by BACHEM
(Germany).
High Cell Density Fermentation for the Production of rSmCI/N23A
and Human CPA4
The expression of rSmCI N23A was carried out in 2.5 l fermenters (B.E. Maru-
bishi, Tokyo, Japan), with 1.5 l working volume, using the following culture
media: CaSO4$2H2O, 0.2 g/l; K2SO4, 4.5 g/l; MgSO4$7H2O, 3.7 g/l; KCl,
Structure
Crystal Structure of SmCI-hCPA41.2 g/l; and H3PO4, 7.0 ml/l. After sterilization, pH was adjusted to 5.0 with the
controlled addition of ammonium hydroxide solution. The inocula were propa-
gated in shaker flasks with 300 ml of YPD medium at 250 rpm and 28C for
24 hr. Temperature and pH were kept constant at 28C and pH 5.0, respec-
tively, along the fermentation. Initial growth was supported on glycerol as a
carbon source, and after a sharp rise in the dissolved oxygen concentration
value, indicating glycerol exhaustion, methanol addition was started at a con-
stant flow of 3 ml/l1 h1, a value increased in 1 ml/l1 h1every 24 hr. Total
duration of induction withmethanol was 48 hr. The supernatants obtained after
fermentation were purified by combining two-ion exchange chromatography
(Streamline Direct HST column; General Electric, USA) with aQSepharose col-
umn (General Electric, USA) (Alonso del Rivero et al., 2012). All procedures
described for inhibitor production were followed by measurement of the inhib-
itory activity against trypsin according to Alonso del Rivero et al., 2012.
The heterologous expression of human CPA4 was carried in Pichia pastoris
system using protocols described by Covaleda et al., 2012. The extracellular
expression of the enzyme was following by SDS PAGE. hCPA4 was purified
by combining hydrophobic interaction chromatography (TOYOPEARL Butyl
650M sepharose column, Sigma Aldrich USA) with anion exchange chroma-
tography (TSK-GEL DEAE-5PW column, Tosoh Biociencies, Japan) according
to the procedures described by Covaleda et al., 2012. The enzyme was acti-
vated with trypsin following the procedures described by Covaleda et al.,
2012. hCPA purity and activity were evaluated with SDS-PAGE and with
hydrolysis of the synthetic substrate AAFP (Pallare`s et al., 2005).
Heterologous Expression of the N-Terminal Mutant of rSmCI N23A:
rSmCI DIS N23A
To obtain the mutant with deletion of the first two amino acids, Ile1 and Ser2, a
similar strategy used to generate the mutant N23A variant (termed SmCI-
N23A) was carried out (Alonso del Rivero et al., 2012). As the last step of
PCR, the mutagenic sense primer 50 TCTCTCGAG AAAAGAGTTTGTGATT
TGCCAGCTGAT 30 (from residues 3 to 9 of SmCI) and the antisense primer
50-CCTTCGCGGCCGCCTAGCAAGCATT-30 (from residues 163 to 165 of
SmCI) were used. In all cases, restriction sites for Xho I andNot I were included
in the sense and antisense primers, respectively, that were allowed to clone
into pPICZaA vector. The cloning strategy was performed following similar
protocols to those used for rSmCI (Alonso del Rivero et al., 2012). The protein
was expressed in the Pichia pastoris system according to the established pro-
cedure described for rSmCI-N23A. The purification of rSmCI DIS N23A
included the combination of two ionic chromatographies, similar to that
used for the nonglycosylated inhibitor (Alonso del Rivero et al., 2012).
Inhibitory Activity of Recombinant Protein
Inhibition assays were performed by preincubating the inhibitor with the
enzymes for 10 min at room temperature before adding the substrate. The
inhibitory activity was evaluated against human CPA4, bovine pancreatic
bCPA1, as well as serine proteases such as trypsin and porcine pancreatic
elastase. The activity versus CPA-like enzymes ([bCPA1] 2.86 3 108M,
[hCPA4] 5.76 3 108M) was determined using the substrate AAFP N-(4-
methoxyphenylazoformyl)-L-phenylalanine (0.1 mM in the assay). Hydrolysis
of substrates was followed at 350 nm at 15 s intervals for 5 min at 25C
(19 3 106 mM1cm1) in a kinetic spectrophotometer (Pharmacia-Biotech,
Sweden) (Alonso del Rivero et al., 2012).
The activities of serine proteases were assayed on the following substrates:
bovine pancreatic trypsin (EC. 3.4.21.4; 7.1 3 108 M in the assay) by moni-
toring esterase activity against BAPA (1.0 mM in the assay) and porcine
pancreatic elastase (EC. 3.4.21.36; 8.4 3 108 M in the assay) on MeOSuc-
(L-Ala)2-L-Pro-L-Val-p-nitroanilide as substrate (1 mM in the assay) (Alonso
del Rivero et al., 2012). All assays were performed at 25C for 3 min. The
time needed to reach inhibition equilibrium was previously determined for
each assay by preincubating SmCI with the enzymes for 1, 5, 10, or 20 min
before substrate addition.
Dissociation Constants
Inhibition constants (Ki) for the complexes formed by the inhibitors with the
different enzymes were determined using a describedmethod for tight binding
inhibition (Copeland, 2000). Different amounts of inhibitor were preincubated
for 10 min with the enzymes. At each concentration, residual activity (vi/vo)Structure 21, 1was measured against the specific substrate (using a substrate concentration
equivalent to 1 KM for each enzyme). The experimental points were adjusted to
the equation described for tight binding mechanisms (Copeland, 2000) by
nonlinear fitting using the GRAPHPAD v5 (Motulsky, 2007). True Ki values
were calculated using the equation: Ki = Kiapp/([S0]/(KM)+1), incorporating
the [S0] used and the KM value for each enzyme.
Complex Formation
The SmCI (N23A)-hCPA4 complex was formed by incubating equimolar quan-
tities of inhibitor and enzyme in 50mMTris-HCl pH 8.5, 250mMNaCl for 2 hr at
4C. The complex formed was purified using a size-exclusion chromatography
column (HiLoad Superdex 75 26/60; GE Healthcare, UK) equilibrated with the
same buffer of complex formation. Elution peaks corresponding to the com-
plex, free enzyme, and inhibitor were analyzed with SDS-PAGE and MALDI-
TOF MS. The hCPA4-SmCI(N23A) complex was concentrated to 12.0 mg/ml
using an Amicon Ultra-4 centrifugal filter (Millipore, USA).
Crystallization and Diffraction Data Collection
Crystals of the complex between SmCI (N23A) and hCPA4 were obtained at
18C by sitting drop vapor diffusion methods. The reservoir solution contained
3.5 MNaCl and 0.1 MHEPES pH 7.5. Single crystals appeared after 24 hr from
equal volumes of protein solution (12 mg/ml in 5 mM Tris pH 8.5, 50 mM NaCl)
and reservoir solution. Crystals were cryoprotected in reservoir buffer contain-
ing 12% glycerol and flash-frozen in liquid nitrogen before diffraction analysis.
Diffraction data were recorded from cryo-cooled crystals (100K) at Grenoble
beamline ID23-2. Data were integrated and merged using XDS (Kabsch,
2010) and scaled, reduced, and further analyzed using CCP4 (Winn et al.,
2011; Table 1).
Structure Determination and Refinement
The structure for the complex SmCI (N23A)-hCPA4 was determined from the
X-ray data at 2.2 A˚ by molecular replacement using the PDB from hCPA4
(PDB code 4A94) as amodel (Molrep;Winn et al., 2011). The result of molecular
replacement allowed the manual building of the SmCI inhibitor, and the
improvement of the complex was performed using COOT (Emsley et al.,
2010). Refinement utilized CNS (Brunger, 2007) and Phenix (Adams et al.,
2010). Ramachandran analysis shows that 92.90% of residues (432) are in
preferred regions, 6.45% of residues (30) are in allowed regions, and 0.65%
of residues (3) are in outlier regions. Refinement and data statistics are pro-
vided in Table 1.
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